Stephen Kaldor's most recent trade in Crinetics Pharmaceuticals Inc was a trade of 12,500 Stock Option (right to buy) done . Disclosure was reported to the exchange on June 19, 2020.
Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
---|---|---|---|---|---|---|---|---|---|---|
Crinetics Pharmaceuticals Inc | Stephen Kaldor | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jun 2020 | 12,500 | 12,500 | - | - | Stock Option (right to buy) |